Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.68 |
| ▸ | MAPT | P10636 | 4/20 | 0.68 |
| ▸ | MEN1 | O00255 | 4/20 | 0.68 |
| ▸ | LMNA | P02545 | 3/20 | 0.68 |
| ▸ | BLM | P54132 | 3/20 | 0.68 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.68 |
| ▸ | TSHR | P16473 | 2/20 | 0.68 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.68 |
| ▸ | MPO | P05164 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | THRB | P10828 | 2/20 | 0.62 |
| ▸ | RECQL | P46063 | 2/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.62 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.62 |
| ▸ | CASP6 | P55212 | 1/20 | 0.62 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18029267 | 1.00 | KMT2A (0.68) | KMT2AKDM4EMAPTMEN1LMNA | |
| SCHEMBL30084863 | 1.00 | KMT2A (0.68) | KMT2AKDM4EMAPTMEN1LMNA | |
| SCHEMBL1114867 | 1.00 | KMT2A (0.68) | KMT2AKDM4EMAPTMEN1LMNA | |
| SCHEMBL7480432 | 0.86 | KMT2A (0.63) | KMT2AKDM4EMAPTMEN1LMNA | |
| SCHEMBL30356567 | 0.86 | KMT2A (0.63) | KMT2AKDM4EMAPTMEN1LMNA | |
| SCHEMBL27917618 | 0.86 | KMT2A (0.63) | KMT2AKDM4EMAPTMEN1LMNA | |
| SCHEMBL7480435 | 0.86 | KMT2A (0.63) | KMT2AKDM4EMAPTMEN1LMNA | |
| SCHEMBL458570 | 0.86 | KMT2A (0.63) | KMT2AKDM4EMAPTMEN1LMNA | |
| SCHEMBL18029241 | 0.86 | KMT2A (0.63) | KMT2AKDM4EMAPTMEN1LMNA | |
| SCHEMBL458569 | 0.86 | KMT2A (0.63) | KMT2AKDM4EMAPTMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250064783-A1 | Compositions of Matter and Pharmaceutical Compositions | PSILERA INC. | 2025-02-27 | — | — | US | claimed |
| US-20240417764-A1 | METHODS FOR THE PRODUCTION OF TRYPTOPHANS, TRYPTAMINES, INTERMEDIATES, SIDE PRODUCTS AND DERIVATIVES | MIAMI UNIVERSITY | 2024-12-19 | — | — | US | claimed |
| EP-4426818-A2 | METHODS FOR THE IMPROVED PRODUCTION OF PSILOCYBIN AND INTERMEDIATES | MIAMI UNIVERSITY (US) | 2024-09-11 | — | — | EP | claimed |
| EP-4426676-A2 | METHODS FOR THE PRODUCTION OF TRYPTOPHANS, TRYPTAMINES, INTERMEDIATES, SIDE PRODUCTS AND DERIVATIVES | MIAMI UNIVERSITY (US) | 2024-09-11 | — | — | EP | claimed |
| WO-2023081837-A9 | METHODS FOR THE PRODUCTION OF TRYPTOPHANS, TRYPTAMINES, INTERMEDIATES, SIDE PRODUCTS AND DERIVATIVES | MIAMI UNIVERSITY (US) | 2024-03-14 | — | — | WO | claimed |
| EP-4208445-A1 | HALOGENATED PSILOCYBIN DERIVATIVES AND METHODS OF USING | Enveric Biosciences Canada Inc. (CA) | 2023-07-12 | — | — | EP | claimed |
| WO-2022150854-A9 | SYSTEMS AND METHODS FOR PHARMACEUTICAL PRODUCTION OF PSILOCYBIN AND INTERMEDIATES OR SIDE PRODUCTS | MIAMI UNIVERSITY (US) | 2023-07-06 | — | — | WO | claimed |
| WO-2023130076-A2 | TARGETS AND PATHWAYS FOR THE PRODUCTION OF ALKALOIDAL COMPOUNDS | Empyrean Neuroscience, Inc. (US) | 2023-07-06 | — | — | WO | claimed |
| CN-116348106-A | Halogenated nupharicin derivatives and methods of use | 恩维瑞克生物科学加拿大公司 | 2023-06-27 | — | — | CN | claimed |
| WO-2023081837-A2 | METHODS FOR THE PRODUCTION OF TRYPTOPHANS, TRYPTAMINES, INTERMEDIATES, SIDE PRODUCTS AND DERIVATIVES | MIAMI UNIVERSITY (US) | 2023-05-11 | — | — | WO | claimed |
| JP-4641942-B2 | — | — | 2011-03-02 | — | — | JP | claimed |
| US-20080194553-A1 | compounds that are capable of increasing the serum level of insulin-like growth factor 1 (IGF-1) for the preparation of a therapeutical composition,in the form of a food supplement, for the treatment of subjects suffering from serious fatigue and exhausting symptoms, burn-out and chronic fatigue syndrome | VEIJLEN N.V. (NL) | 2008-08-14 | — | — | US | claimed |
| US-20070299128-A1 | Use of Tryptophan Derivatives for the Specific Cytostatic Treatment of Serotonin-Producing Tumors | WALTHER DIEGO | 2007-12-27 | — | — | US | claimed |
| CN-1938018-A | Use of compounds capable of increasing serum IGF-1 levels for the preparation of therapeutic compositions for the treatment of various disease states associated with decreased IGF-1 serum levels in humans and animals | VEIJLEN LTD (AN) | 2007-03-28 | — | — | CN | claimed |
| EP-1670444-A2 | USE OF INDOLEACETIC ACID DERIVATIVES WHICH INCREASE THE SERUM IGF-1 LEVEL FOR THE PREPARATION OF A THERAPEUTICAL COMPOSITION FOR TREATMENT OF VARIOUS DISEASES | Veijlen N.V. (AN) | 2006-06-21 | — | — | EP | claimed |
| WO-2005039546-A2 | USE OF INDOLEACETIC ACID DERIVATIVES WHICH INCREASE THE SERUM IGF-1 LEVEL FOR THE PREPARATION OF A THERAPEUTICAL COMPOSITION FOR TREATMENT OF VARIOUS DISEASES | VEIJLEN N.V. (AN) | 2005-05-06 | — | — | WO | claimed |
| EP-1368027-B1 | USE OF TRYPTOPHAN DERIVATIVES FOR THE SPECIFIC CYTOSTATIC TREATMENT OF SEROTONIN-PRODUCING TUMORS | MAX DELBRUECK CENTRUM (DE) | 2004-08-04 | — | — | EP | claimed |
| US-20040097576-A1 | Use of tryptophan derivatives for the specific cytostatic treatment of serotonin-producing tumors | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2004-05-20 | — | — | US | claimed |
| EP-1368027-A2 | USE OF TRYPTOPHAN DERIVATIVES FOR THE SPECIFIC CYTOSTATIC TREATMENT OF SEROTONIN-PRODUCING TUMORS | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (DE) | 2003-12-10 | — | — | EP | claimed |
| WO-2002074309-A2 | USE OF TRYPTOPHAN DERIVATIVES FOR THE SPECIFIC CYTOSTATIC TREATMENT OF SEROTONIN-PRODUCING TUMORS | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2002-09-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250064783-A1 | Compositions of Matter and Pharmaceutical Compositions | TPH1, HTR1B, HTR2C | KMT2A 2419/4885KDM4E 2638/4885MAPT 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.